Anderson; Niall Andrew
Patent Applications and Registrations
Patent applications and USPTO patent grants for Anderson; Niall Andrew.The latest application filed is for "heterocyclic amides as kinase inhibitors".
- Anderson; Niall Andrew - Stevenage GB
| Patent | Date |
|---|---|
| Heterocyclic Amides as Kinase Inhibitors App 20210253532 - Anderson; Niall Andrew ; et al. | 2021-08-19 |
| Naphthyridines As Integrin Antagonists App 20210206758 - ANDERSON; Niall Andrew ; et al. | 2021-07-08 |
| Heterocyclic amides as kinase inhibitors Grant 10,899,716 - Anderson , et al. January 26, 2 | 2021-01-26 |
| Chemical compounds Grant 10,793,559 - Anderson , et al. October 6, 2 | 2020-10-06 |
| Heterocyclic Amides As Kinase Inhibitors App 20200165205 - ANDERSON; Niall Andrew ; et al. | 2020-05-28 |
| Heterocyclic amides as kinase inhibitors Grant 10,590,085 - Anderson , et al. | 2020-03-17 |
| Chemical Compounds App 20200071311 - ANDERSON; Niall Andrew ; et al. | 2020-03-05 |
| Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases Grant 10,513,517 - Anderson , et al. Dec | 2019-12-24 |
| Naphthyridines as integrin antagonists Grant 10,487,080 - Anderson , et al. Nov | 2019-11-26 |
| Chemical compounds Grant 10,457,674 - Anderson , et al. Oc | 2019-10-29 |
| Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists Grant 10,450,312 - Anderson , et al. Oc | 2019-10-22 |
| NOVEL COMPOUNDS avB6 INTEGRIN ANTAGONISTS. App 20190275016 - ANDERSON; Niall Andrew ; et al. | 2019-09-12 |
| Compounds .alpha..sub.v.beta..sub.6 integrin antagonists Grant 10,342,783 - Anderson , et al. July 9, 2 | 2019-07-09 |
| Naphthyridines As Integrin Antagonists App 20190112306 - ANDERSON; Niall Andrew ; et al. | 2019-04-18 |
| Naphthyridine Derivatives As Alpha V Beta 6 Integrin Antagonists For The Treatment Of E.g. Fibrotic Diseases App 20190048005 - ANDERSON; Niall Andrew ; et al. | 2019-02-14 |
| Chemical Compounds App 20190040051 - ANDERSON; Niall Andrew ; et al. | 2019-02-07 |
| Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases Grant 10,144,733 - Anderson , et al. De | 2018-12-04 |
| Naphthyridine Derivatives Useful As Alpha-v-beta-6 Integrin Antagonists App 20180291022 - ANDERSON; Niall Andrew ; et al. | 2018-10-11 |
| NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS App 20180271845 - Anderson; Niall Andrew ; et al. | 2018-09-27 |
| Naphthyridine derivatives useful as .alpha..sub.v.beta..sub.6 integrin antagonists Grant 10,023,568 - Anderson , et al. July 17, 2 | 2018-07-17 |
| Compounds alpha v beta 6 integrin antagonists Grant 10,004,724 - Anderson , et al. June 26, 2 | 2018-06-26 |
| Compounds .alpha..sub.v.beta..sub.6 integrin antagonists Grant 10,000,489 - Anderson , et al. June 19, 2 | 2018-06-19 |
| Heterocyclic Amides As Kinase Inhibitors App 20180134665 - ANDERSON; Niall Andrew ; et al. | 2018-05-17 |
| Compounds .alpha..sub.v .beta..sub.6 integrin antagonists Grant 9,956,209 - Anderson , et al. May 1, 2 | 2018-05-01 |
| NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS App 20170298063 - Anderson; Niall Andrew ; et al. | 2017-10-19 |
| NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS App 20170290818 - ANDERSON; Niall Andrew ; et al. | 2017-10-12 |
| Naphthyridine Derivatives As Alpha V Beta 6 Integrin Antagonists For The Treatment Of E.g. Fibrotic Diseases App 20170291899 - ANDERSON; Niall Andrew ; et al. | 2017-10-12 |
| NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS App 20170290817 - Anderson; Niall Andrew ; et al. | 2017-10-12 |
| Naphthyridine Derivatives Useful As Alpha-v-beta-6 Integrin Antagonists App 20160280705 - Anderson; Niall Andrew ; et al. | 2016-09-29 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 